CAMBRIDGE, Mass., June 14 /PRNewswire-FirstCall/ -- Advanced Magnetics (Amex: AVM - News) today announced that the independent Data Monitoring Committee (DMC) providing oversight for the ferumoxytol Phase III iron replacement therapy program met and informed the company that it has carefully reviewed the cumulative safety data from the ferumoxytol Phase III studies and identified no safety concerns. The DMC also recommended the continuation of the ferumoxytol Phase III studies with no modifications.
